MEVES PHARMACEUTICALS
Meves Pharmaceuticals is developing nucleoside based therapies for mitochondrial DNA (mtDNA) depletion syndromes (MDS or MDDS), a category of severe genetic diseases. The initial focus is on therapy tailored specifically to treat patients with Thymidine Kinase 2 (TK2) deficiency, a discrete monogenic disorder associated with profound skeletal myopathy.
MEVES PHARMACEUTICALS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2016-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.mevespharma.com
Total Employee:
1+
Status:
Active
Contact:
510-375-1669
Email Addresses:
[email protected]
Total Funding:
10.91 M USD
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Current Employees Featured
